Thanks to all of you, or at least a large majority--our D&D newsletter has reached a milestone. And now I must upgrade to the paid Mail Chimp tier. Because of this epic "things are getting real" status I am working with new formats, original content, and video streams from some of the dozen plus conferences and panel discussions I am invited to attend each year.
While the learning curve is being tamed, I will release some of the new content and topics in a weekend early release here on the blog. Eventually, this will only go to newsletter folks--you should receive something for your loyalty and I hope you find the resource helpful.
If you would like me to feature an article you have written and are shamelessly proud of--simply ask. Speaking of shameless, I stole this format from American Express OPEN.
If you want to subscribe or share the link --> here is the link to the newsletter
Healthcare for people, not consumers...
DATA TALKS, MEOPLE PUMBLE
Trends with benefits: improving surveys
Why we should listen to Martin Shkreli By Mike Rea
Meetings and opportunities to connect...
LET'S BUILD A BETTER FOOD POLICY: 2017 Food Tank Summit DC
HIMSS 17 WHERE THE BRIGHTEST MINDS IN HEALTH AND IT MEET
Insight of the week
Although the FDA has traditionally focused on the safety and efficacy of drugs relative to placebo, there are abundant good reasons for the agency to push industry and other study sponsors to use active controls in type 2 diabetes studies. The major clinical role of the new drugs is as alternative treatments, not as therapies for patients who otherwise would not be treated with drugs.